<DOC>
	<DOCNO>NCT00089024</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Giving combination chemotherapy radiation therapy surgery may shrink tumor remove . PURPOSE : This phase II trial study well give combination chemotherapy together radiation therapy work treat patient may undergo surgery locally advance pancreatic cancer .</brief_summary>
	<brief_title>Combination Chemotherapy , Radiation Therapy Treating Patients With Locally Advanced Pancreatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine antitumor clinical benefit response neoadjuvant chemoradiotherapy comprise gemcitabine , fluorouracil , leucovorin calcium , oxaliplatin patient potentially resectable locally advanced adenocarcinoma pancreas . - Determine toxic effect regimen patient . - Determine achieve steady-state plasma level gemcitabine fluorouracil patient correlate plasma level clinical toxicity associate regimen . - Determine potential importance polymorphic variation genomic DNA pertinent gene ( whose protein product target antineoplastic drug use study ) response toxicity regimen patient . - Determine gene expression profile primary metastatic pancreatic tumor treatment regimen . OUTLINE : - Neoadjuvant chemotherapy : Patients receive gemcitabine IV 30 minute fluorouracil IV continuously 24 hour day 2 9 , leucovorin calcium orally day 1 8 IV day 2 9 . Treatment repeat every 21 day 2 course absence disease progression unacceptable toxicity . - Neoadjuvant chemoradiotherapy : Beginning day 42 , patient undergo chemoradiotherapy comprise oxaliplatin IV 2 hour day 42 , 49 , 56 , 63 , 70 , 77 fluorouracil IV continuously day 42-78 external beam radiotherapy . - Surgery : Patients undergo surgical resection 42-56 day completion chemoradiotherapy . - Adjuvant chemotherapy : After post-operative recovery , patient receive 2 additional course gemcitabine , fluorouracil , leucovorin calcium . If surgical resection possible , patient stable responsive disease resume gemcitabine , fluorouracil , leucovorin calcium indefinitely absence disease progression unacceptable toxicity . Patients follow every 3 month . PROJECTED ACCRUAL : A total 50 patient accrue study .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis adenocarcinoma pancreas Locally advance disease Potentially resectable disease No early stage resectable disease No evidence distant metastases liver peritoneal area accord image study laparoscopic stag PATIENT CHARACTERISTICS : Age 19 Performance status Karnofsky 60100 % Life expectancy Not specify Hematopoietic Absolute granulocyte count ≥ 2,000/mm^3 Platelet count ≥ 100,000/mm^3 Hepatic Bilirubin ≤ 2.0 mg/dL ( absence biliary obstruction ) If biliary obstruction present , patient must undergo biliary decompression Bilirubin ≤ 3.0 mg/dL biliary drainage establish Renal Creatinine ≤ 1.6 mg/dL Cardiovascular No symptomatic congestive heart failure No unstable angina pectoris No serious uncontrolled cardiac arrhythmia Other Not pregnant nursing No uncontrolled illness No active ongoing infection require IV antibiotic No mark intolerance 5fluoropyrimidines ( i.e. , fluorouracil , floxuridine , capecitabine , fluorocytosine ) No allergy sulfonamide , aspirin , nonsteroidal antiinflammatory drug No allergy platinum compound antiemetic appropriate administration conjunction study chemotherapy No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer adequately treat noninvasive carcinoma PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior chemotherapy pancreatic cancer Endocrine therapy Not specify Radiotherapy No prior abdominal radiotherapy Surgery Not specify Other No concurrent nonsteroidal antiinflammatory medication</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>adenocarcinoma pancreas</keyword>
	<keyword>stage II pancreatic cancer</keyword>
	<keyword>stage III pancreatic cancer</keyword>
</DOC>